Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab
Treatment by association of complete surgical excision of the lesions and intraperitoneal immunotherapy using Catumaxomab for patients with gastric peritoneal carcinomatosis
Patients With Gastric Peritoneal Carcinomatosis
DRUG: Catumaxomab 100µg|DRUG: Catumaxomab 140µg
Progression Free Survival, every 3 months for the first two years
Progression Free Survival, every 3 months for the first two years then every 4 months on year 3 then every 6 months on year 4 and 5
Treatment by association of complete surgical excision of the lesions and intraperitoneal immunotherapy using Catumaxomab for patients with gastric peritoneal carcinomatosis